substantial side effects that can delay bringing forward research that can, in fact, identify a new treatment. >> how does it cdelay? >> two ways, if people with alzheimer's think there's already a good treatment they may not volunteer for other studies. new studies that go forward typically take a new drug and compare it to a placebo or enactive drug. in this case, if this is approved, or has been approved, now studies will have to compare to this drug. that can give you a very biased analysis of a new drug. the second problem is not only do we have loss of enthusiasm for potential volunteers for studies, but we may have loss of enthusiasm from the nih and other people who fund this type of research thinking well there's already something there, we don't need to move forward so our momentum could be